Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.57 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701628 | 0.99 | MEN1 (0.74) | MEN1KMT2AHRH3DRD3PSMB1 | |
| SCHEMBL15701623 | 0.90 | HRH3 (0.73) | MEN1KMT2AHRH3DRD3ALDH1A1 | |
| SCHEMBL15701622 | 0.87 | MEN1 (0.61) | MEN1KMT2AHRH3DRD3ALDH1A1 | |
| SCHEMBL492315 | 0.86 | MEN1 (0.97) | MEN1KMT2AHRH3PSMB1PSMB5 | |
| SCHEMBL5857827 | 0.85 | MEN1 (0.94) | MEN1KMT2AHRH3PSMB1PSMB5 | |
| SCHEMBL19287693 | 0.84 | MEN1 (1.00) | MEN1KMT2AHRH3PSMB1PSMB5 | |
| SCHEMBL15704237 | 0.84 | KDM4E (0.68) | MEN1KMT2AHRH3DRD3L3MBTL1 | |
| SCHEMBL14970452 | 0.83 | HRH3 (0.89) | HRH3DRD3 | |
| SCHEMBL15704202 | 0.82 | KDM4E (0.66) | MEN1KMT2AHRH3DRD3L3MBTL1 | |
| SCHEMBL21730111 | 0.82 | MEN1 (0.67) | MEN1KMT2AHRH3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | MEN1 4470/4885KMT2A 2047/4885HRH3 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.